Beam Therapeutics (BEAM) Stock Price, News & Analysis

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last twelve months. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BEAM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BEAM, but not buy additional shares or sell existing shares.
View BEAM analyst ratings or view top-rated stocks.

13 brokerages have issued twelve-month price objectives for Beam Therapeutics' stock. Their BEAM share price targets range from $20.00 to $57.00. On average, they anticipate the company's stock price to reach $41.00 in the next year. This suggests a possible upside of 70.3% from the stock's current price.
View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts.

Beam Therapeutics' stock was trading at $27.22 at the start of the year. Since then, BEAM shares have decreased by 11.6% and is now trading at $24.07.
View the best growth stocks for 2024 here.

Beam Therapeutics saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 13,450,000 shares, a decline of 6.1% from the March 15th total of 14,320,000 shares. Based on an average daily volume of 1,390,000 shares, the days-to-cover ratio is presently 9.7 days.
View Beam Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BEAM earnings forecast.

Beam Therapeutics Inc. (NASDAQ:BEAM) released its earnings results on Tuesday, February, 27th. The company reported $1.73 earnings per share for the quarter, topping the consensus estimate of ($0.69) by $2.42. The firm earned $316.20 million during the quarter, compared to analyst estimates of $34.16 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 15.90% and a negative net margin of 35.09%. Beam Therapeutics's quarterly revenue was up 1481.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.54) earnings per share.

ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Innovation ETF (ARKK), Horizon Kinetics Medical ETF (MEDX), WisdomTree BioRevolution Fund (WDNA) and Jacob Forward ETF (JFWD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

Beam Therapeutics (BEAM) raised $101 million in an initial public offering on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Beam Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (2.89%), SteelPeak Wealth LLC (0.01%), DLK Investment Management LLC (0.01%), Thrive Wealth Management LLC (0.01%) and Riverview Trust Co (0.00%). Insiders that own company stock include Amy Simon, Christine Bellon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends.

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.